Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Julphar
Boehringer Ingelheim
UBS
US Army
Cantor Fitzgerald
Cipla
McKesson
Queensland Health

Generated: February 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMBRUVICA

« Back to Dashboard

Clinical Trials for Imbruvica

Trial ID Title Status Sponsor Phase Summary
NCT01779791 A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma Completed Pharmacyclics LLC. Phase 2 The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
NCT01779791 A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma Completed Janssen Research & Development, LLC Phase 2 The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
NCT01829568 Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma Active, not recruiting Celgene Corporation Phase 1 This phase I clinical trial studies the side effects and best dose of lenalidomide and ibrutinib when given together with rituximab in treating patients with previously untreated stage II-IV follicular lymphoma. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can find cancer cells and help kill them. Giving lenalidomide and ibrutinib together with rituximab may work well in treating follicular lymphoma.
NCT01829568 Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma Active, not recruiting National Cancer Institute (NCI) Phase 1 This phase I clinical trial studies the side effects and best dose of lenalidomide and ibrutinib when given together with rituximab in treating patients with previously untreated stage II-IV follicular lymphoma. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can find cancer cells and help kill them. Giving lenalidomide and ibrutinib together with rituximab may work well in treating follicular lymphoma.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Imbruvica

Condition Name

Condition Name for Imbruvica
Intervention Trials
Chronic Lymphocytic Leukemia 23
Mantle Cell Lymphoma 10
Small Lymphocytic Lymphoma 9
Recurrent Mantle Cell Lymphoma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Imbruvica
Intervention Trials
Lymphoma 50
Leukemia, Lymphoid 41
Leukemia, Lymphocytic, Chronic, B-Cell 40
Leukemia 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Imbruvica

Trials by Country

Trials by Country for Imbruvica
Location Trials
United States 307
Spain 18
Canada 10
Australia 7
Germany 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Imbruvica
Location Trials
Texas 28
Ohio 21
California 19
New York 15
Massachusetts 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Imbruvica

Clinical Trial Phase

Clinical Trial Phase for Imbruvica
Clinical Trial Phase Trials
Phase 4 1
Phase 3 13
Phase 2 48
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Imbruvica
Clinical Trial Phase Trials
Recruiting 67
Not yet recruiting 31
Active, not recruiting 9
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Imbruvica

Sponsor Name

Sponsor Name for Imbruvica
Sponsor Trials
National Cancer Institute (NCI) 38
Pharmacyclics LLC. 19
M.D. Anderson Cancer Center 18
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Imbruvica
Sponsor Trials
Other 85
Industry 77
NIH 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Mallinckrodt
US Army
US Department of Justice
McKesson
Federal Trade Commission
Cantor Fitzgerald
QuintilesIMS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.